Research & development has been the foundation of Boehringer Ingelheim's success and continues to be the major driver of innovative, new medicines for the treatment of diseases with an unmet therapeutic need. Furthermore, in our constant quest for pharmaceutical innovation we have successful ongoing collaborations and are actively seeking new collaborations with external partners, ranging from academic institutions to biopharmaceutical enterprises and start-up companies.
More than 8,000 highly qualified people of Boehringer Ingelheim’s over 47,700 employees worldwide work at either one of our three major research & development sites (Biberach and Ingelheim, Germany, Ridgefield, USA, and Vienna, Austria) or two support centres (Kobe, Japan and Milan, Italy).
Currently, we work on more than 100 projects in our research organization. In 2014 our R&D spending reached 2.7 billion Euro which represents about 20 % of our net sales. Boehringer Ingelheim has a long-standing reputation in supporting basic science in academia. During the past decade, from 2005 to 2014, we conducted or sponsored 1,414 studies with 115 compounds in 95 countries from all regions of the world.
We are striving to expand our international network of academic, industry and not-for-profit partners who share our goal to meet the medical needs of the patients – We think together we can improve the health of people around the world. Currently, more than 50% of our early-mid stage pipeline is filled with products that are derived from external innovation with our partners.